Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
63%(5 trials)

Phase Distribution

Ph phase_4
3
30%
Ph phase_2
1
10%
Ph phase_1
1
10%
Ph phase_3
5
50%

Phase Distribution

1

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
5(50.0%)
Phase 4Post-market surveillance
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(1)
Other(1)

Detailed Status

Completed8
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 21 (10.0%)
Phase 35 (50.0%)
Phase 43 (30.0%)

Trials by Status

unknown110%
withdrawn110%
completed880%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT04930094Phase 3

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Completed
NCT05767034Phase 3

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Completed
NCT04488185Phase 4

An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound

Withdrawn
NCT02798211Phase 4

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Completed
NCT04967950Phase 1

An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients

Unknown
NCT03568136Phase 2

Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis

Completed
NCT02267135Phase 3

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

Completed
NCT02690701Phase 4

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

Completed
NCT01555125Phase 3

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

Completed
NCT01806597Phase 3

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10